ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 2433
Evaluation Of The Two-Step Referral Strategy For Axial Spondyloarthritis In The Spondyloarthritis Caught Early Cohort
Abstract Number: 2434
Syndesmophyte Distribution Along The Vertebral Rim In Ankylosing Spondylitis Is Non-Random
Abstract Number: 2435
Prevalence Of Inflammatory Lesions MRI-Spine In Patients With Chronic Back Pain Of ≤2 Years Duration Included In The SPACE-Cohort
Abstract Number: 2436
Classification Of Axspa Based On Positive Imaging (Radiographs and/or MRI of the Sacroiliac Joints) By Local Rheumatologists Or Radiologists Versus Central Trained Readers In The DESIR-Cohort
Abstract Number: 2437
Prevalence Of Axial Spondyloarthritis In The United States Among Patients With Chronic Back Pain and Other Spondyloarthritis-Related Features
Abstract Number: 2438
Effectiveness Of Exercise Program  in Ankylosing Spondylitis: Meta-Analysis Of Randomized Controlled Trials
Abstract Number: 2439
Smoking Was Not Associated With Response To Adalimumab Therapy In Patients With Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2440
Is There a Role For Etoricoxib In Patients With Axial Ankylosing spondylitis  Refractory To Traditional NSAID?
Abstract Number: 2441
Do Postural Deformities In Patients With Ankylosing Spondylitis Cause Balance Problems?
Abstract Number: 2442
[18F]-Fluoride PET/CT Assessment In Patients Responding To The ASAS Criteria For Spondyloarthritis Despite Negative Sacroiliac Joint MRI
Abstract Number: 2443
Prevalence Of Coronary Heart Disease In Spondyloarthopathies  may Be Increased Due To Higher Prevalence Of Risk Factors As Well As The Disease Itself- A Retrospective Analysis At Single VA Medical Center
Abstract Number: 2444
The Contribution Of Disease Activity On Function and Quality Of Life In Patients With Ankylosing Spondylitis; Investigating Causality By Using Structural Equation Model
Abstract Number: 2445
Acute Phase Reactant As a Marker Of Anti-Drug Antibody Formation In Ankylosing Spondylitis
Abstract Number: 2446
Opiate Use In Patients With Ankylosing Spondylitis
Abstract Number: 2447
Disease Activity Is Associated With Development Of Inflammatory Bowel Disease In Ankylosing Spondylitis: 12-Year Results From OASIS
Abstract Number: 2448
Cardiovascular Disease Is Associated With Worse Functional Outcomes In Ankylosing Spondylitis
Abstract Number: 2449
Patient-Reported Disease Activity and Outcome In Male Versus Female Patients Of The Groningen Leeuwarden Axial Spondyloarthritis (GLAS) Cohort
Abstract Number: 2450
Differences and Similarities Of Spondyloarthritis Classification Subgroups Defined By The Assessment Of Spondyloarthritis International Society (ASAS)
Abstract Number: 2451
Work Instability Scores In Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Are Equal and Higher Than In Psoriatic Arthritis
Abstract Number: 2452
Effects Of Smoking In Patients With Axial Spondyloarthritis – Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis – Receiving Anti-TNF therapy
Abstract Number: 2453
Identification Of Determinants Of The Functional Outcome In Patients With Early Axial Spondyloarthritis: Results From The German Spondyloarthritis Inception Cohort
Abstract Number: 2454
High Prevalence Of Left Ventricular Diastolic Dysfunction In Patients With Ankylosing Spondylitis
Abstract Number: 2455
The Lipid Profile Improves In Patients With Ankylosing Spondylitis Responding To TNF Blocking Therapy
Abstract Number: 2456
Prevalence Of Overweight and Obesity and The Relation To Disease Activity, Physical Function and Quality Of Life In Patients With Axial Spondyloarthritis
Abstract Number: 2457
Ankylosing Spondylitis and a Diagnostic Dilemma: Coccydynia
Abstract Number: 2458
Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care
Abstract Number: 2459
Improvement In Physical Function, Health-Related Quality Of Life, and Work Productivity With Adalimumab Treatment In Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2460
Spondyloarthritis Epidemiology and Burden Phase 2 [SPEED 2] Study: Disease Progression In Axial Spondyloarthropathy (SpA)
Abstract Number: 2461
Quality Of Life, Physical Function and Symptoms In Non-Radiographic Axial Spondyloarthritis:The Patient Perspective
Abstract Number: 2462
Comparison Of Tumor Necrosis Factor Inhibitor Use For Ankylosing Spondylitis At University Rheumatology Clinics In Scotland and Oregon
Abstract Number: 2463
Tomosynthesis As a New Diagnostic Tool For Evaluation Of Ankylosing Spondylitis With Modified Stoke Ankylosing Spondylitis Spinal Score: A Comparison With Plain Radiographs
Abstract Number: 2464
Late-Onset Ankylosing Spondylitis Has Distinctive Presenting Symptoms and a Higher Inflammatory Burden
Abstract Number: 2465
Prevelance Of Inflammatory Back Pain and Axial Spondyloarthritis Among University Employees In Izmir, Turkey
Abstract Number: 2466
Long Term Efficacy Over Five Years Of Adalimumab In Patients With Active Non – Radiographic Axial Spondyloarthritis
Abstract Number: 2467
Response to Tumor Necrosis Factor inhibitors In Axial Spondyloarthritis: Does Sacroiliitis Make Any Difference?
Abstract Number: 2468
The Prevalence Of Sjogren’s Syndrome In Patients With Ankylosing Spondylitis
Abstract Number: 2469
Radiographic Sacroiliitis Progression In An Early Spondyloarthritis Cohort
Abstract Number: 2470
Combined Axial and Peripheral Involvement Is Associated With Miscegenation In A Large and Heterogeneous Brazilian Cohort Of 1505 Patients With Spondyloarthritis
Abstract Number: 2471
Prevalence Of Inflammatory Back Pain In Psoriatic Arthritis: The Prepare Study
Abstract Number: 2472
Disease Burden Is Similar Between Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis and Independent Of Gender Influences
Abstract Number: 2473
Comparison Of The Two Subtypes Of Axial Spondyloarthritis Patients Fulfilling The Imaging Arm Based On Radiographic and MRI Findings
Abstract Number: 2474
Fat Mass and Resistin: Predictive Factors For Anti-TNF Therapy Response In Ankylosing Spondylitis Patients
Abstract Number: 2475
Relationship Between Extra-Articular Manifestations and Disease Activity In Patients Diagnosed With New-Onset Spondyloarthropathy In a Cohort In Spain
Abstract Number: 2476
Periodontal Disease Is Not Associated With Ankylosing Spondylitis and TNF-Alpha Blockers Usage In Korea
Abstract Number: 2477
Impact Of Stressful Life Events On Disease Activity In Spondyloarthritis: Results Of The Coenv-2 Prospective Cohort Study
Abstract Number: 2478
Clinical Characteristics Of Patients With Early Spondyloarthritis. Results From a Specialized Consultation In a Clinical Hospital
Abstract Number: 2479
Adalimumab Significantly Reduces Inflammation In Active Ankylosing Spondylitis: An Ultrasound Study
Abstract Number: 2480
Predicting Progression Of Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2481
External Validation Of The Spondyloarthritis Radiography Online Reference Module For Training Readers To Score The Modified Stoke Ankylosing Spondylitis Score
Abstract Number: 2482
Which Contextual Factors Have An Important Influence On Work Outcome In Patients With Ankylosing Spondylitis. A Systematic Literature Review
Abstract Number: 2483
Periarticular Bone Gain In Early Psoriatic Arthritis But Not In Rheumatoid Arthritis Following Anti-Rheumatic Treatment As Measured By Digital X-Ray Radiogrammetry
Abstract Number: 2484
Immunogenicity Of TNFα Blockers In Patients With Psoriatic Arthritis
Abstract Number: 2485
High Incidence Of Disease Recurrence After Discontinuation Of Disease Modifying Anti-Rheumatic Drug Treatment In Patients With Psoriatic Arthritis In Remission
Abstract Number: 2486
Clinical Performance Of 4 Methods For Detecting Latent Tuberculosis Infection (LTbI) In Patients With Active Chronic Inflammatory Arthritis Taking TNFα Blockers
Abstract Number: 2487
Role Of IL-33 In The Development Of Premature Atherosclerosis In Psoriatic Arthritis Patients

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology